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Abstract 47 
OBJECTIVE: To investigate the prevalence of hypertensive disorders of pregnancy (HDP), 48 
and the respective roles of PCOS, obesity, lifelong weight gain (WG) and hyperandrogenemia 49 
in the disease development by age 46. 50 
METHODS: The Northern Finland Birth Cohort 1966, with follow-up at ages 14, 31 and 46, 51 
including women with (n=408) and without (n=3373) HDP diagnosis. HDP diagnosis was 52 
combined from the questionnaire data at age 46, hospital discharge records and Finnish Medical 53 
Birth Registers. Women with both oligo-amenorrhea and hirsutism at age 31 or with PCOS 54 
diagnosis by age 46 (n=279) were compared with the women without PCOS (n=1577). 55 
RESULTS: Women with PCOS had an increased HDP risk (odds ratio [OR]=1.56 56 
[95%CI:1.03-2.37]), but the association disappeared after adjusting for BMI at age 31. The risk 57 
for HDP was not increased among normal weight PCOS women. The increase of BMI (kg/m2) 58 
from age 14 to 31 was significantly greater in both PCOS (median (interquartile range): 59 
5.94(3.69;11.1), p<0.001) and non-PCOS (4.89(3.21;7.57), p<0.001) women with HDP and 60 
also in PCOS women without HDP (4.59(2.40;7.54), p=0.009) compared to non-PCOS without 61 
HDP. Among women with PCOS, BMI increase was greater in women with than without HDP 62 
(5.94(3.69;11.1) vs 4.59(2.40;7.54), p=0.015). Hyperandrogenemia at ages 31 or 46 did not 63 
associate with HDP (OR=1.44 [95%CI: 0.98-2.11]). 64 
CONCLUSION: Obesity and weight gain from adolescence to age 46, but not PCOS per se or 65 
hyperandrogenemia, were associated with an increased risk of HDP. There was a strong 66 
synergistic association of PCOS and obesity regarding HDP risk. 67 
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Introduction 68 
Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting 5 to 15% of women at 69 
fertile age (Archer, Chang, 2004, Franks, 1995, Kjerulff, Sanchez-Ramos & Duffy, 2011). 70 
PCOS is defined by the presence of two of the following criteria: (i) polycystic ovaries (PCO); 71 
(ii) oligo-amenorrhea (OA) or amenorrhea; and/or (iii) clinical or biochemical evidence of 72 
hyperandrogenism (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 73 
2004, Teede, Missio et al. 2019). The syndrome is associated with overweight and obesity in 74 
20% to 80% of the women depending on the studied population and diagnostic criteria used 75 
(Sam, 2007, Lim et al., 2019). Importantly, insulin resistance is a pivotal disorder in PCOS, 76 
affecting approximately 25% to 70% of the women with the syndrome and is exacerbated by 77 
overweight and obesity (Diamanti-Kandarakis, 2007, Sam, 2007). 78 
Hypertensive disorders of pregnancy (HDP) complicate 5-10% of all pregnancies 79 
(Hashemi et al., 2013). Hypertensive disorders of pregnancy include chronic hypertension 80 
(blood pressure of at least >140/90 mmHg before pregnancy or before 20 weeks of gestation), 81 
preeclampsia (new onset of hypertension and proteinuria after 20 weeks of gestation), 82 
superimposed preeclampsia (chronic hypertension in association with preeclampsia) and 83 
gestational hypertension (defined according to the same criteria but without proteinuria) (Wang 84 
et al., 2013, Davison et al., 2004a (American College of Obstetricians and Gynecologists, Task 85 
Force on Hypertension in Pregnancy 2013)). All these disorders are associated with increased 86 
maternal and fetal morbidity and mortality during pregnancy and can also affect the future 87 
health of both the mother and child (Mannisto et al., 2013). Women with a history of HDP seem 88 
to be at higher risk of chronic hypertension, dyslipidemia, cardiovascular diseases (CVDs), type 89 
2 diabetes mellitus and kidney disease in later life (Hashemi et al., 2013, Mannisto et al., 2013). 90 
HDP, especially pre-eclampsia, predisposes fetus to intrauterine growth restriction and these 91 
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children are also reported to have an increased risk for CVDs later in life. (Davison et al., 2004b, 92 
(Herrera-Garcia, Contag 2014)).  93 
Recent meta-analyses have suggested that PCOS per se is associated with an 94 
increased risk of pregnancy induced hypertension (PIH) and preeclampsia ((Bahri Khomami, 95 
Joham et al. 2019), Boomsma et al., 2006, Qin et al., 2013, Kjerulff, Sanchez-Ramos & Duffy, 96 
2011), although conflicting results have also been obtained (Altieri et al., 2010, Haakova et al., 97 
2003, Mikola et al., 2001). Of note, in some studies, the association between PCOS and HDP 98 
has been confounded by multiple factors such as a higher multiple pregnancy rate, parity, age 99 
and body mass indexes (BMI) (Boomsma et al., 2006, Mumm et al., 2015). It has also been 100 
suggested that the increased risk of HDPs in PCOS may be linked mainly to obesity or 101 
hyperandrogenemia, but not specifically to the syndrome itself. 102 
This study has two main aims: firstly, to investigate in a population-based follow-103 
up cohort study, whether women with PCOS experience an increased prevalence of HDP during 104 
their reproductive life. Secondly, to identify the impact of factors associated with PCOS, 105 
particularly obesity and hyperandrogenemia, on the development of HDP. More specifically, 106 
we wanted to explore the significance of weight gain from adolescence to adulthood regarding 107 
the emergence of HDP both in PCOS and in non-PCOS women. 108 
 109 
METHODS 110 
Data collection and study population 111 
The study population consisted of the Northern Finland Birth Cohort 1966 (NFBC66), a unique 112 
population-based, follow-up cohort of subjects (12058 born alive during 1966 in two 113 
northernmost provinces of Finland, of these 5889 females). Collection of this database began 114 
at the 24th gestational week and was supplemented by data collected at ages 14, 31 and 46. At 115 
age 14, in 1990, the adolescent females (n=5455, 94.6%) answered a postal questionnaire, with 116 
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the help of their parents, including questions about weight and height. In 1997, at age 31, a 117 
postal questionnaire, including questions about health, behavior, work and social background, 118 
was sent to 5608 women and 4523 (81%) of them responded. In addition, those living in 119 
Northern Finland or in the Helsinki metropolitan area (n=4074) were invited to a clinical 120 
examination. Of these, 3127 (77%) women participated in a clinical examination including 121 
anthropometric measurements and blood samples for hormonal and metabolic parameters. 122 
Again, at age 46, a new large questionnaire including all main health issues and an invitation to 123 
clinical examination was sent to 5123 women. Of these, 3706 (72.3%) answered the 124 
questionnaire and 3280 women (64.0%) participated in the clinical examinations, including also 125 
blood samples. (Figure 1). When gathering the final study population women without deliveries 126 
were excluded from the analyses. 127 
In all clinical examinations, participants’ weight (kg) was measured with a 128 
regularly calibrated, digital scale. Height (cm) was measured twice by using standard and 129 
calibrated stadiometer and the average of the measurements was calculated. Body mass index 130 
(BMI) was calculated (kg/m2) and women who were overweight (BMI ≥25 kg/m2) or obese 131 
(BMI >30 kg/m2) were identified. BMI values at ages 31 and 46 from clinical examination and 132 
postal questionnaire were combined to create a variable where clinically measured BMI was 133 
primarily used and self-reported BMI used if measured BMI was not available. The clinically 134 
measured and self-reported BMIs did not differ (Ollila, Piltonen et al. 2016, Koivuaho, Laru et 135 
al. 2019). Weight changes (median ±SD) between ages 14-31, 31-46 and 14-46 as well as 136 
increase in waist circumference between ages 31 and 46 were calculated in each study group. 137 
Definition of HDP diagnosis  138 
The diagnosis of HDP had to be assessed at least in two of the three following sources to be 139 
considered as reliable: the Finnish Medical Birth Register (FMBR), the hospital discharge 140 
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register (HDR) or the questionnaire at age 46. The process is described in more detail in 141 
Supplemental Figure 1.  142 
Data on women´s pregnancies and deliveries until the end of 2013 was obtained 143 
from the FMBR. The FMBR, active since 1987, is currently run by the National Institute for 144 
Health and Welfare. For each delivery in Finland, a structured form for FMBR is completed by 145 
the delivery hospital, including demographic and health data of the mother, the course and 146 
complications of the pregnancy (including HDP diagnosis) and the delivery, and the perinatal 147 
health of the newborn until the age of seven days. The FMBR is supplemented with data 148 
compiled by the Population Register Centre on live births and by Statistics Finland on stillbirths 149 
and deaths during the first week of life. After these additions, the registration of birth is 100%. 150 
The HDR was checked for the data available (years 1972-2017) and the ICD-8, 151 
ICD-9 and ICD-10 diagnostic codes for HDPs were identified.  152 
Questions about HPD (chronic hypertension, PIH and preeclampsia) in the 46-153 
years questionnaire were asked as follows: If you have been pregnant, have you been diagnosed 154 
during pregnancy with 1) hypertension (including preexisting chronic hypertension and PIH) 155 
2) hypertension and proteinuria (=pre-eclampsia)?  156 
According to the questionnaire, 665 women were diagnosed with HDP by age 46. 157 
Of those women, 358 were not given a formal diagnosis of HDP to the HDR or the FMBR. 158 
Their medical records were therefore checked, and for 51 of those 358 the diagnosis of HDP 159 
was confirmed in the patients’ records. The remaining women whose diagnosis could not be 160 
confirmed were excluded from further analyses (n=307). After the exclusion of the women with 161 
a diagnosis of HDP from only one source (n=522), the final study group therefore comprised 162 
408 women with a confirmed diagnosis of HDP. The women without diagnosis of HDP from 163 
any of these three sources were considered as control women (n=3373, Supplemental Figure 164 
1). 165 
8 
Definition of PCOS diagnosis 166 
 At age 31, the questionnaire included two questions on hirsutism (H) and oligo-167 
amenorrhea (OA): 1) is your menstruation cycle over twice a year more than 35 days? and 168 
2) do you have excessive body hair? Of the women who responded to the questionnaire 169 
(excluding women using hormonal contraception, n=1459 and not permitting the use of 170 
their data for data analysis, n=41), 10.4% (n=321) reported isolated H, 10.2% (n=330) 171 
isolated OA and 3.4% (n=125) both OA and H (Koivunen et al., 2008, Rantakallio, 1988, 172 
Taponen et al., 2004). Women with only one PCOS symptom were excluded from the 173 
analyses. At age 46, the question on self-reported PCOS was inquired as follows: Have you 174 
been diagnosed with polycystic ovaries (PCO) and/or PCOS? Women with either both 175 
symptoms at age 31 and/or self-reported PCO/PCOS diagnosis by age 46 were classified 176 
as cases (n=279), which is consistent with both the National Institutes of Health and the 177 
Rotterdam criteria for diagnosis of PCOS (Rotterdam ESHRE/ASRM-Sponsored PCOS 178 
Consensus Workshop Group, 2004, ZAWADSKI JK, 1992). Women without any PCOS 179 
symptoms at age 31 and without self-reported diagnosis of PCOS by age 46 were classified 180 
as “non-PCOS controls” (N=1577, Figure 1). 181 
Final study population 182 
The study population was further divided into four groups: women with PCOS with HDP 183 
(n=36), women with PCOS without HDP (n=154), non-PCOS women with HPD (n=161) and 184 
non-PCOS women without HDP (n=1045) (Figure 1). 185 
Laboratory methods 186 
Biochemical assays and laboratory methods of the clinical examination (at age 31) are detailed 187 
elsewhere (Taponen et al., 2003). Sex hormone binding globulin (SHBG) at the age of 46 years 188 
was analyzed by chemiluminometric immunoassay (Immulite 2000, Siemens Healthcare, 189 
Llanberis, UK). Analytical sensitivity of method was 0.02 nmol/l. The intra-assay coefficients 190 
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of variation (CVs) of the method were 4.5% and 9.7% for concentrations 5.6 and 89.3 nmol/l, 191 
respectively. The inter-assay CVs of the method were 4.1% and 5.3% for concentrations 8.4 192 
and 38.5 nmol/L, respectively. Serum samples for assay of total testosterone (T) at ages 31 and 193 
46 were analyzed by using Agilent triple quadrupole 6410 LC-MS equipment with an 194 
electrospray ionization source operating in positive-ion mode (Agilent Technologies, 195 
Wilmington, DE, USA). Multiple reaction monitoring was used to quantify T by using 196 
trideuterated T (d3-T), with the following transitions: m/z 289.2 to 97 and 289.2 to 109 for T 197 
and 292.2 to 97 and 292.2 to 109 for d3-T. The intra-assay CVs of the method were 5.3%, 1.6% 198 
and 1.2% for T at 0.6, 6.6 and 27.7 nmol/l, respectively. 199 
A woman was considered as having an elevated T levels if T was over 2.3 nmol/l 200 
at age 31 (upper limit in our accredited laboratory in fertile age women) or over 1.7 nmol/l at 201 
age 46. The cut-off value for T at age 46 was determined according to the upper limit of 97.5% 202 
reference range in non-PCOS women in the study population. The free androgen index (FAI) 203 
was calculated by using the equation 100×T (nmol/l)/SHBG (nmol/l). 204 
Statistical methods 205 
The differences in distributions of clinical characteristics were tested by using nonparametric 206 
Mann-Whitney U test, when appropriate, otherwise a t-test was used. The p-values were further 207 
adjusted for BMI at ages 31 and 46 using univariate general linear modelling (ANCOVA). 208 
Categorical data were analyzed using cross-tabulation and Pearson’s Chi-squared (χ2) test. 209 
Continuous data are presented as medians with lower (25th) and upper quartiles (75th) 210 
(interquartile range, IQR). 211 
The whole study population was also stratified into quartiles regarding serum total 212 
T level and free androgen index (FAI) at age 31 and 46. Chi-squared (χ2) test’s Linear-by-Linear 213 
association was used to identify the trend of HDP prevalence across these quartiles. The p-214 
values were further adjusted for BMI at age 31 and 46 using a binary logistic regression model. 215 
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 Binary logistic regression models were employed to estimate the factors 216 
associated with HDP. Several covariates were also included into the models, including 217 
consumption of alcohol, smoking and education status at age 46. The results are reported as 218 
odds ratios (ORs) with 95% confidence intervals (95% CIs). A p-value <.05 was considered 219 
statistically significant. Statistical analyses were performed using IBM SPSS Statistics 23.0 220 
(SPSS Inc., Chicago, IL, USA). 221 
Ethical approval 222 
The Ethics Committee of the Northern Ostrobothnia Hospital District approved the study and 223 
written informed consent was obtained from all subjects. All subjects received written and oral 224 
information and gave their written consent to use all data. 225 
 226 
RESULTS 227 
Association of PCOS with HDP 228 
The prevalence of HDP was 14.1% (n=197/1396) in the whole population. Women with PCOS 229 
presented more often HDP compared with the non-PCOS controls 18.9% vs 13.3%, 230 
respectively, (p=0.044, Figure 2) and displayed also a slightly increased risk of HDP (OR=1.56 231 
[95% CI: 1.03-2.37]). The risk between the groups, however, was abolished after adjustment 232 
for BMI at age 31. (Figure 3A). The results were similar when replacing BMI at age 31 by BMI 233 
at age 46 or by waist circumference at age 31 or 46 (data not shown).  When obese (BMI ≥30 234 
kg/m2 vs BMI≤30) women with PCOS were compared with the non-PCOS controls, the 235 
association with HDP was significant in obese PCOS women at ages 31 (OR=6.40 236 
[95%CI:3.10-13.23]) (Figure 3A). 237 
Comparison of women with PCOS with and without HDP (Table 1, Figures 4A and 4B) 238 
When comparing women with PCOS with or without HDP, BMI was significantly higher at 239 
ages 14 (p=0.022), 31 (p=0.001) and 46 (p<0.001) and waist circumference was significantly 240 
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greater at age 46 (p=0.003) in PCOS cases with HDP. They also had greater weight gain from 241 
adolescence to late adulthood (Table 1, Figure 4A). However, the increase of waist 242 
circumference (age 31-46) did not significantly differ between the two groups (Figure 4B). At 243 
ages 31 and 46, FAI was significantly higher in women with PCOS and HDP (p=0.015 and 244 
p=0.020, respectively), but statistical significance was lost after adjustment for BMI. 245 
 246 
Comparison of women with HDP with and without PCOS (Table 1 and Figures 4A and 4B)  247 
When comparing HDP women with PCOS to those without PCOS, BMI was significantly 248 
higher in the PCOS group at ages 14 (p=0.018), 31 (p<0.001), and 46 (p=0.003) and their weight 249 
gain was greater from age 14 to 31 (p=0.033). (Table 1 and Figure 4A). Waist circumference 250 
was significantly greater at ages 31 (p=0.021) and 46 (p=0.011). The increase of waist 251 
circumference between ages 31 and 46 did not differ and the pattern of this increase was very 252 
similar between the two groups (Figure 4B). 253 
Further, in HDP women with PCOS, the serum levels of T were significantly 254 
higher (p=0.011) at age 31, and FAI was significantly higher at age 31 (p=0.002) and 46 255 
(p=0.007) than in HDP women without PCOS. After BMI adjustments, statistical significance 256 
was lost regarding serum levels of T (p=0.061) but the difference in FAI remained significant 257 
at both ages 31 (P=0.012) and 46 (p=0.037). 258 
Comparison of non-PCOS women with and without HDP (Table 1, Figure 3B) 259 
In the non-PCOS women with HDP, BMI was significantly higher at ages 14 (p=0.011), 31 260 
(p<0.001) and 46 (p<0.001), and waist circumference was significantly greater at ages 31 261 
(p=0.005) and 46 (p<0.001) compared to the non-PCOS women without HDP. Weight gain was 262 
significantly greater between ages 14-31 (p<0.001) and 14-46 (p<0.001) in the HDP group.  In 263 
the non-PCOS women at age 31, the risk of HDP increased along with BMI class (Table 1, 264 
Figure 3B). 265 
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Association of hyperandrogenemia with HDP in the whole population 266 
In the whole population, women with elevated serum T (>2.3nmol/l at age 31 or >1.7nmol/l at 267 
age 46) did not have a significantly greater risk of HDP compared to non-hyperandrogenic 268 
controls. The levels of FAI expressed as medians were significantly higher at ages 31 (4.53 269 
[2.62; 7.63] vs. 3.76 [2.43; 5.72], p=0.009) and 46 (1.72 [1.25; 2.46] vs. 1.52 [1.06; 2.16], 270 
p<0.001) in women with HDP compared with women without HDP and the significance 271 
remained at age 46 after adjustment for BMI (p=0.042). The prevalence of HDP in the T 272 
quartiles was not significantly linearly associated at age 31 (p=0.337) or at age 46 (p=0.895). 273 
In the FAI quartiles, the prevalence of HDP were significantly linearly associated at age 31 274 
(p=0.019), and at age 46 (p<0.001), but overall significance was lost after adjustment for BMI 275 
(Supplemental Figure 2). 276 
 277 
Discussion 278 
This large follow-up, cohort study indicates that the increased risk of HDP in PCOS can mostly 279 
be attributed to overweight or obesity and that normal weight women with PCOS seem not to 280 
be at increased risk for developing HDP. More specifically, our study revealed also that weight 281 
gain from adolescence until the end of reproductive life was the most significant parameter 282 
associated with HDP both in PCOS women and in non-PCOS women. Lastly, our results could 283 
not confirm any significant association of hyperandrogenemia with the development of HDP.   284 
Comparison with other studies 285 
The total prevalence of HDP was 14.1% in our study population, which is relatively high when 286 
compared to other studies - typically reported a prevalence of HDP are between 5 and 10% 287 
(Hutcheon, Lisonkova & Joseph, 2011, Hashemi et al., 2013, Umesawa, Kobashi, 2017). It is 288 
of note, however, that direct comparison of HDP prevalence across populations from different 289 
countries is challenging, given the considerable heterogeneity in screening approaches, 290 
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diagnostic criteria, and underlying population characteristics. Moreover, it seems that the 291 
prevalence of HDP is increasing widely due to the rising burden of obesity in women of 292 
reproductive age (Hutcheon, Lisonkova & Joseph, 2011). 293 
In the whole group of women with PCOS, the risk of HDP was significantly 294 
increased but in overweight/obese women with PCOS the risk was more than three-fold 295 
compared to normal weight non-PCOS women. These findings are in line with the conclusions 296 
of recent meta-analyses, suggesting that women with PCOS have an increased risk of 297 
developing PIH and preeclampsia (Bahri Khomami, Joham et al. 2019), Boomsma et al., 2006, 298 
Qin et al., 2013, Kjerulff, Sanchez-Ramos & Duffy, 2011). In the present study, however, the 299 
difference disappeared when comparing overweight/obese PCOS women with 300 
overweight/obese non-PCOS women, and the prevalence of HDP was not increased among 301 
normal-weight PCOS women compared to their normal weight non-PCOS counterparts. Similar 302 
results were found in the non-PCOS groups when comparing the risk of HDP in obese or 303 
overweight with their normal weight counterparts, suggesting that the risk of HDP is mostly 304 
attributable to overweight/obesity, in line with some earlier data (Ye et al., 2014, Fuchs et al., 305 
2017). The diverging conclusions of the aforementioned meta-analyses could be explained by 306 
the fact that the majority of the eligible studies either did not take into account confounding 307 
factors such as BMI, were of retrospective study design and included a relatively small sample 308 
size. Only few previous studies have addressed the possible interaction of BMI with PCOS 309 
regarding the risk of HDP. Lonnebotn et al also reported an increased risk of HDP in obese 310 
women with PCOS but not in normal weight or overweight women with PCOS (Lonnebotn et 311 
al., 2018). However, that study reported also increased risk in underweight (BMI <18.5 kg/m2) 312 
women, whereas there were no underweight women with both PCOS and HDP in our study. All 313 
in all, the results of the present study indicate that increased BMI significantly enhances the 314 
risk of HDP and that PCOS seems to synergistically increase this risk. 315 
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In previous literature, there is a lack of long-term follow up studies investigating 316 
the association of lifelong increase of weight or of waist circumference with the risk of HDP. 317 
In this study, the women with HDP (PCOS and non-PCOS) experienced a significantly greater 318 
increase in weight from adolescence to late adulthood compared with women without HDP 319 
(both PCOS and non-PCOS, respectively). Interestingly, the pattern of increase in waist 320 
circumference between ages 31 and 46 was mostly associated with HDP, but not with PCOS 321 
status. These findings further strengthen the role abdominal obesity and insulin resistance, as a 322 
pivotal factor associated with the development of HDP. The existence of a complex synergistic 323 
interrelationship between PCOS, abdominal obesity and weight gain are most likely risk factors 324 
for these alterations.  325 
In the whole study population, the risk of HDP was not significantly increased in 326 
the group of women with elevated serum T levels compared with controls. However, 327 
hyperandrogenemia assessed by FAI was significantly associated with HDP, and both PCOS 328 
and non-PCOS women with HDP had higher values of FAI compared with non-PCOS women 329 
without HDP. Again, after adjusting for BMI, hyperandrogenemia lost its statistical 330 
significance. Some previous studies have suggested that the hyperandrogenic PCOS phenotypes 331 
are associated with higher prevalence of HDP, especially preeclampsia, compared to 332 
normoandrogenic phenotypes (Palomba et al., 2010, Naver et al., 2014) but other studies have 333 
produced conflicting results (Mumm, Jensen et al. 2015). Hyperandogenism has been 334 
associated with preeclampsia also in the absence of PCOS (Carlsen, Romundstad et al. 2005, 335 
Perez-Sepulveda, Monteiro et al. 2015, Ghorashi, Sheikhvatan 2008, Hakim, Padmanabhan et 336 
al. 2017). A possible explanation for these observations may be that placental aromatase (the 337 
enzyme responsible for the conversion of androgens to estrogens) is deficient in placental 338 
ischemia and preeclamptic pregnancy (Perez-Sepulveda et al. 2017), thus explaining the 339 
observed elevation of maternal androgens during preeclampsia. Elevated androgens have also 340 
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been postulated to play an important role in the etiology of preeclampsia, although the 341 
mechanism is not clear (Gorashi and Sheikhvatan 2008). In the present study, the lack of 342 
association between hyperandrogenemia and HDP may be partly due to the fact that we were 343 
not able to differentiate the diagnosis of pre-eclampsia from the other causes of HDP. Based on 344 
the present and those earlier results, the role of hyperandrogenemia in the pathogenesis of HDP 345 
remains therefore under debate and needs further research to be clarified. 346 
Strengths and limitations 347 
The main strength of this study is the prospective population-based cohort design with the 348 
longest follow-up time compared with previous studies investigating the relationship between 349 
BMI and HDP in women with and without PCOS. All subjects were of Caucasian ethnicity and 350 
living in the same area during the same time period. The participation rates for the clinical 351 
examinations and questionnaires at ages 31 and 46 were remarkably high and anthropometric 352 
parameters were mostly clinically measured. In Finland, free of charge, mandatory follow-up 353 
of pregnancy in health care centers and practically free-of-charge maternal care in public 354 
hospitals is offered equally to all pregnant women, which enabled us to perform data collection 355 
on pregnancy complications in virtually all women participating in the 46-year questionnaire. 356 
By taking advantage of FMBR, HDR and the questionnaire data we were able to have an 357 
accurate estimate of HDP in our study population as HDP diagnosis was set only if it was found 358 
in at least two out of the three sources. Moreover, our study included careful adjustments for 359 
possible confounders allowing us to identify the respective effects of PCOS per se and other 360 
risk factors, such as obesity, hyperandrogenemia and weight gain from adolescence to late 361 
adulthood, on risk of having developed HDP during reproductive life. Lastly, the measurements 362 
of total T were performed by using LC-MS equipment, which has been considered as the 363 
“golden standard” for measuring total T in women. 364 
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A potential limitation of our study is that documenting symptoms of PCOS at age 365 
31 and PCOS diagnosis at age 46 was based on questionnaires. Hirsutism might be over-366 
reported by self-estimation and ovarian ultrasonography was not available to aid the diagnosis 367 
of PCOS. However, the combined presence of oligo/amenorrhea and hirsutism fulfils both 368 
Rotterdam and National Institute of Health (NIH) criteria for PCOS, and we have previously 369 
shown that co-existence of self-reported oligo-amenorrhea and hirsutism can identify women 370 
with the typical endocrine, metabolic and psychological profiles of PCOS (Taponen, 371 
Martikainen et al. 2003, Taponen, Ahonkallio et al. 2004),(Karjula, Morin-Papunen et al. 2017). 372 
It was not possible to differentiate between the diagnosis of chronic hypertension, PIH and 373 
preeclampsia, as all these conditions were included as one identity into the HDP diagnosis. 374 
Finally, even though BMI values were collected at ages 31 and 46 from clinical examination 375 
and postal questionnaire, BMI data during pregnancy were not available. 376 
 377 
Conclusions 378 
Polycystic ovary syndrome per se was not associated with an increased risk of HDP, but there 379 
was a strong synergistic association between PCOS, obesity and weight gain for the 380 
development of this pregnancy complication. The present results emphasize the importance of 381 
weight management prior pregnancy to reduce the incidence of HDP, an important factor cause 382 
of postnatal morbidity. The role of hyperandrogenemia in the pathophysiological process of 383 
HDP could not be confirmed, remaining under debate with further research being needed to 384 
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Table 1 Clinical characteristics of non-PCOS women and women with PCOS, sorted according to status of hypertensive disorder of pregnancy.  
Clinical  Non-PCOS Non-PCOS P-valuea PCOS P-valueb PCOS P-valuec  P-valued P-valuee 
Characteristics  without HDP with HDP (BMI-adj.  without HDP (BMI-adj. with HDP (BMI-adj. (BMI-adj. (BMI-adj. 
  (n=521-1039d) (n=85-160d) p-value f) (n=88-147d) p-value f) (n=21-35d) p-value f) p-value f) p-value f) 
BMI (kg/m2) 14 yr  18.7 (17.4; 20.2) 19.2 (17.9; 20.9) .011 19.3 (18.0; 20.6) .006 20.4 (18.6; 22.8) <.001 .022 .018 
BMI (kg/m2) 31 yr  22.6 (20.7; 24.9) 24.0 (21.8; 26.7) <.001 24.1 (21.5; 27.2) <.001 28.0 (22.4; 33.9) <.001 .001 <.001 
BMI (kg/m2) 46 yr  25.2 (22.6; 28.6) 26.9 (23.9; 30.5) <.001 26.2 (23.7; 30.3) .002 31.4 (26.1; 37.3) <.001t <.001t .003t 
Waist (cm) 31 yr  76.0 (70.0; 83.0) 78.0 (72.5; 85.3) .005 81.0 (71.0; 92.0) <.001 83.5 (75.0; 98.0) <.001 .113 .021 
Waist (cm) 46 yr  83.5 (77.0; 93.5) 90.0 (79.5; 99.0) <.001 86.5 (79.5; 97.8) .020 94.5 (83.6; 115.1) .001t .003t .011t 
Change in BMI (kg/m2) 14-31 yr 3.83 (2.27; 5.74) 4.89 (3.21; 7.57) <.001 4.59 (2.40; 7.54) .009 5.94 (3.69; 11.1) <.001 .015 .033 
Change in BMI (kg/m2) 31-46 yr 2.40 (0.81; 4.19) 2.65 (0.97; 5.61) .068 2.19 (0.71; 4.60) .745 2.96 (0.14; 4.40) .895 .801 .479 
Change in BMI (kg/m2) 14-46 yr 6.33 (3.90; 9.33) 7.54 (5.32; 11.62) <.001 7.21 (4.16; 10.5) .151 9.82 (6.23; 14.6) <.001t .001t .073t 
Change in waist (cm) 31-46 yr 8.30 (2.60; 14.0) 8.80 (3.00; 16.0) .352 8.00 (3.00; 15.0) .692 11.0 (5.00; 19.9) .203t .247t .691t 
Total testosterone (nmol/l) 31 yr 1.80 (1.40; 2.30) 1.90 (1.40; 2.40) .527 (.979) 2.00 (1.70; 2.80) <.001 (.003) 2.60 (1.95; 3.10) .002t (.083) .284t (.558) .011t (.061) 
FAI 31 yr  3.75 (2.57; 5.44) 4.41 (2.67; 6.00) .097 (.985) 5.08 (3.14; 7.64) .002 (.372) 10.31 (4.55; 13.31) .001t (.013) .015t (.189) .002t (.012) 
Total testosterone (nmol/l) 46 yr 0.82 (0.62; 1.05) 0.80 (0.61; 1.07) .963 (.664) 0.86 (0.68; 1.05) .277 (.236) 0.97 (0.72; 1.13) .092t (.066) .315t (.232) .113t (.063) 
FAI 46 yr  1.53 (1.06; 2.22) 1.63 (1.17; 2.24) .324 (.727) 1.62 (1.29; 2.25) .064 (.347) 2.17 (1.43; 3.41) .001 (.037) .020 (.176) .007 (.037) 
Data is expressed as medians (interquartile ranges). The significance test used was Mann-Whitney U test, when a rule |skewness/standard error of skewness|>1.96 was valid for the dependent 
variable, otherwise t-test was used (t-sign). aP-value: non-PCOS with HDP compared to non-PCOS without HDP. bP-value: PCOS without HDP compared to non-PCOS without HDP. cP-value: 
PCOS with HDP compared to non-PCOS without HDP. dP-value PCOS with HDP compared to PCOS without HDP. eP-value PCOS with HDP compared to non-PCOS with HDP. fThe numbers 
of women in separate analyses varies due to non-response to some items. fThe results were adjusted for BMI at age 31 and 46 years using univariate general linear modelling (ANCOVA). BMI: 
body mass index; FAI: free androgen index; HDP: hypertensive disorder of pregnancy; PCOS: polycystic ovary syndrome; SHBG: sex hormone binding globulin. 
Figure 1. Flowchart of the study population. Data on pregnancies, deliveries and HDP until the end of 2013 was obtained from the questionnaire at age 46, the Finnish Medical 


















FMBR: Finnish Medical Birth Register; H: hirsutism; HDP: hypertensive disorder of pregnancy; HDR: hospital discharge register; OA: oligo-amenorrhea; PCOS: polycystic ovary syndrome. 
Northern Finland Birth Cohort 1966 
Females born alive 
in 1966: 
n=5889 women 
Final Study population: 
PCOS women: n=279 
(154 without HDP, 36 with HDP, 89 data missing) 
Control women: n=1577 




31-year postal questionnaire 
was sent to n=5608 women 
46-year postal questionnaire 
was sent to n=5123 women 
Responded to the postal 
questionnaire: n=4523 
women  
Participated to the clinical 
examinations: n=3127 
women 
Responded to the postal 
questionnaire: n=3706 
women 
Participated to the clinical 
examination: n=3280 women 
Women with OA and H: n=125 
Women with isolated OA: n=330  
Women with isolated H: n=321 
 Control women: n=1577 
Women with PCOS: n=180  
Control women: n=1577 
Did not respond to the PCOS question: 
n=60 
Refused data 
usage: n=41 Did not respond to the OA and H-
questions: n=44 
 
Pregnant or using hormonal 
contraception: n=1459 
 
Did not respond to the PCOS 
question at age 46: n=1139 




usage: n=14 Did not respond to the OA and H 
questions at age 31: n=1429 
(excluded from controls) 
 
Figure 2. Prevalence of HDP in the whole population (n=197/1396, and in women with (n=36/190) and 




























Figures 3A and 3B. Odds ratios (ORs) for hypertensive disorders of pregnancy. 
 
The analyses were done using binary logistic regression. Results were adjusted model 1 (1) for consumption of alcohol, smoking and education or model 2 (2) for 












0 1 2 5 12
The risk of HDP increases
Fig 3A: ORs for HDP for PCOS women vs non-PCOS women and 
according to the BMI class
PCOS vs. non-PCOS (1)
PCOS vs. non-PCOS (2)
PCOS+BMI<25.0 vs. non-
PCOS+BMI<25.0 at age 31 (1)
PCOS+BMI 25-30 vs. non-
PCOS+BMI<25.0 at age 31 (1)
PCOS+BMI≥25.0 vs. non-
PCOS+BMI<25.0 at age 31 (1)
PCOS+BMI≥30.0 vs. non-
PCOS+BMI<30.0 at age 31 (1)
BMI≥30.0 vs. BMI<30.0 at age 31 (1)
PCOS+BMI<25.0 vs. non-
PCOS+BMI<25.0 at age 46 (1)
PCOS+BMI 25-30 vs. non-
PCOS+BMI<25.0 at age 46 (1)
PCOS+BMI≥25.0 vs. non-
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Fig 3B: ORs for HDP in the non-PCOS women in the 



























Figure 4A. Changes in body mass index (BMI) during life in women with PCOS and non-PCOS women according to their HDP status. 
Figure 4B. Changes in waist circumference (cm) between ages 31 and 46 in women with PCOS and non-PCOS women according to their HDP 
status. 
 
BMI and waist circumference values are expressed as medians at each time point (14, 31 and 46 years). The difference in the BMI and waist development between ages 14 and 
46 in each study group was analyzed using the Mann-Whitney U test or t-test.  
Only the P-values for comparison with non-PCOS women without HDP at the same age are presented here. The P-values for differences between the other groups are presented 
in the text and in Table 1. Figures 4A and B: *p < 0.05, **p < 0.01 and ***p < 0.001. 































































































Supplemental figure 1. Flowchart of the HDP diagnosis. Data on HDP until the end of 2013 was 
combined from the questionnaire at age 46, the Finnish Medical Birth Register (FMBR) and the 
Hospital Discharge Register (HDR). The diagnosis for the final study population was assessed if at 














to the 46-year 






Did not display any HDP 
diagnosis according to 
the FMBR or the HDR:          
n=358 
Diagnosis confirmed according to 
the hospital patient records 
n=51 
Diagnosed according to 
- FMBR + HDR n=50  
- FMBR + questionnaire n=9 
- HDR + questionnaire n=244 
- FMBR + HDR + questionnaire n=54 
-  
Final Study population:  
Women with HDP n=408  


















Supplemental figure 2A and 2B. Prevalence of hypertensive disorders of pregnancy (HDP) in different total level of testosterone (A) and free androgen (B) quartiles at ages 31 and 46. 
 
The difference in the prevalence was analyzed using Chi-squared (χ2) test’s Linear-by-Linear association test to identify the trend of HDP prevalence across quartiles. The P-values represent the linear relationship in 
prevalence of HDP across the testosterone quartiles. *The overall BMI adjusted p-value was analyzed using binary logistic regression model. There were 418 subjects per testosterone and 417-418 subjects per FAI 
































A1: Age31 Linear-by-linear association, 
































A2: Age 46 Linear-by-linear association, 
































B1: Age 31 Linear-by-linear association, 































B2: Age 46 Linear-by-linear association, 
p-value <0.001 (0.512*)
Women
with
HDP
